Breaking AI & Tech News Analyzed

Metabolic liver disease, or MASLD, is projected to affect 1.8 billion people worldwide by 2050, according to a recent study. This significant increase is primarily driven by rising obesity and blood sugar levels globally.MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most prevalent and rapidly growing liver conditions worldwide. The condition's prevalence has already seen a 143% increase in just three decades, from 500 million people in 1990 to 1.3 billion people in 2023.The study, published in the Lancet Gastroenterology & Hepatology journal, highlights that high blood sugar is the leading driver of MASLD-related health problems globally, followed by high BMI and smoking. These factors are strongly linked to type 2 diabetes and obesity.Regional disparities exist, with north Africa and the Middle East having disproportionately higher rates of MASLD. However, there have been sharp increases in the number of people affected in countries across the world, including the UK, Australia, and the United States.Despite the growing number of cases, the overall impact on health has remained stable, suggesting that advances in treatment and care are helping people live longer and healthier lives. However, the increasing number of cases still poses a risk of serious complications such as liver cirrhosis or cancer in the future.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

Sam Neill, the veteran actor celebrated for his memorable performances on screen, is set to answer readers' questions in an upcoming interview with The Guardian. Neill's iconic roles include his portrayal in Jurassic Park, where he famously removes his sunglasses and gazes at a towering Brachiosaurus, a scene that has become etched in cinematic history.Born in Northern Ireland and raised in New Zealand, Neill's diverse filmography showcases his versatility as an actor. He has appeared in a range of films, from period dramas like My Brilliant Career to thrillers such as Dead Calm, which is set to be released in 4K later this year. His recent projects include Godzilla x Kong: Supernova, alongside Kaitlyn Dever and Matthew Modine.Neill's career has been marked by his ability to take on idiosyncratic, director-led projects, often playing characters with a unique blend of gruffness and warmth. His performances in Sweet Country and Rams have been particularly noted for their depth and nuance.In addition to his film work, Neill has also made headlines for his memoir, Did I Ever Tell You This?, in which he openly discusses his experience with stage-three blood cancer and his journey towards remission. When asked about his mortality, Neill expressed a pragmatic view, stating, “I’m not afraid to die, but it would annoy me”.Readers are invited to post their questions for Sam Neill by 6pm BST, Thursday 16 April, and The Guardian will publish his answers in their reader interview series. This provides a unique opportunity for fans to engage with one of cinema's most beloved actors and gain insight into his life and career.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.

Malina Lee, a 31‑year‑old wedding baker from San Antonio, joined TikTok in 2020 to pass the lockdown‑induced boredom and promote her business. Four years later, an anonymous commenter called “PickleFart” noticed an asymmetrical neck in one of her videos and suggested she check for a goiter.The tip proved accurate: doctors confirmed thyroid cancer. Lee received prompt treatment and, within a year, was declared cancer‑free. She told the outlet that her oncologist was amazed at how early the disease was caught, crediting the TikTok comment as the catalyst.Lee’s experience is part of a growing trend where TikTok’s hyper‑targeted algorithm surfaces health‑related content that resonates with users’ unnoticed symptoms. In several cases, community members have flagged potential conditions that clinicians initially missed.The “PickleFart” persona belongs to Billie Jean Tuomi, who calls herself the “thyroid avenger.” A thyroid‑cancer survivor herself (diagnosed in 2012), Tuomi now scans videos for neck asymmetry and gently advises creators to seek a thyroid panel—a blood test measuring hormone levels and antibodies. The American Thyroid Association recommends adults start routine thyroid testing at age 35, or annually for high‑risk individuals.Tuomi estimates she has flagged dozens of videos, with at least four confirmed serious thyroid issues, including Lee’s. She stresses she does not claim to diagnose, merely urges viewers to consult a physician. After a viral comment, she received a flood of private messages with neck photos, prompting her to change her username.Lee, inspired by Tuomi’s intervention, has begun commenting on other users’ videos, helping one individual discover an enlarged thyroid that required removal. She describes the process as a “domino effect” of community‑driven health awareness.Medical professionals acknowledge the double‑edged nature of this phenomenon. Craig Mittleman, director of emergency services at Lawrence + Memorial Hospital, notes a rise in patients arriving with self‑diagnoses sourced from social media. While this can empower patients to ask informed questions, it also burdens clinicians with debunking misinformation.Gender disparities amplify the issue: research shows women are more likely to seek health information online, often after feeling dismissed by traditional providers. TikTok user Tori Mosser, a 23‑year‑old filmmaker, credits a direct message suggesting chronic appendicitis for prompting surgery that resolved her chronic vomiting episodes.Both Lee and Mosser emphasize the therapeutic value of finding a supportive community on TikTok, especially for invisible or chronic illnesses that are frequently minimized in clinical settings.

The evening’s television line‑up offers a mix of heartfelt competition, natural‑history wonder and high‑profile live events, giving viewers plenty of reasons to stay tuned.9 pm – Channel 4 – Your Song: Produced by the team behind The Piano, this new talent show invites ordinary Britons to perform the songs that hold personal meaning. Hosted and judged by Alison Hammond, Paloma Faith and Sam Ryder, the series launches from Liverpool with stories ranging from a teenager’s Bocelli tribute to a lift‑engineer’s pipe‑organ showcase, all racing toward a finale at the Hackney Empire.6 pm – BBC One – Secret Garden: David Attenborough returns to domestic natural history, turning his lens on a modest garden in Bristol. The programme explores the hidden dramas of urban foxes, blue tits and goldfinches, revealing how a tiny plot can host an entire ecosystem.7 pm – BBC Two – Olivier Awards 2026: The Royal Albert Hall hosts the 50th anniversary of Britain’s premier theatre awards, with Nick Mohammed as host. Into the Woods and Paddington: the Musical lead the nominations with eleven each, while Elaine Page receives a Special Award. Rumours swirl about a surprise performance from the awards’ most famous marmalade lover.7.40 pm – Channel 4 – The Great Celebrity Bake Off for Stand Up to Cancer: A comforting Sunday tradition returns, featuring celebrity bakers Ralf Little, Mutya Buena and Mark Wright. Their creations—savory pull‑apart rolls and vegan fruit tarts—aim to raise funds for cancer research.8 pm – BBC One – The Other Bennet Sister: This Pride & Prejudice spin‑off follows Ella Bruccoleri’s Mary as she navigates the attentions of Mr Hayward and Mr Ryder, with a storm‑laden hike adding further tension to the series’ impending conclusion.10.15 pm – ITV1 – Savage River: Australian crime drama starring Katherine Langford returns, following ex‑con Miki Anderson as she attempts a fresh start in her hometown, only to become the prime suspect when a new crime erupts.Film choice – Sky Cinema Premiere – Blue Moon (6.10 am & 7.10 pm): Richard Linklater’s melancholy drama, anchored by Ethan Hawke’s transformative performance, imagines a night in the life of struggling Broadway lyricist Lorenz Hart, whose post‑opening despair leads him to a cocktail of regret.4.15 pm – Channel 4 – Soul: Pixar’s latest metaphysical adventure, co‑directed by Pete Docter and Kemp Powers, follows deceased music teacher Joe (voiced by Jamie Foxx) as he navigates a limbo for unborn souls, meeting the reluctant 22 (Tina Fey) in a story that blends child‑friendly wonder with adult reflections on purpose.Live sport: Premier League action kicks off with Sunderland vs Tottenham at 1 pm on Sky Sports Main Event, followed by Chelsea vs Manchester City at 4.25 pm, offering football fans a double‑header of top‑flight drama.

The Caribbean and Latin America are facing a critical moment in their relationship with Cuba, as they succumb to US pressure to expel Cuban doctors. These medical professionals have been a lifeline for many in the region, providing essential healthcare services, particularly in rural and underserved areas. Cuban doctors have been a cornerstone of healthcare in the Caribbean and Latin America, with programs dating back 50 years. However, under pressure from the US, countries such as Guatemala, Honduras, Jamaica, the Bahamas, Antigua and Barbuda, Guyana, and St Vincent and the Grenadines have terminated these agreements. Only St Kitts and Nevis and Trinidad and Tobago have yet to follow. The US has branded these programs "forced labor" and "human trafficking" because the Cuban state retains a share of salaries. However, this ignores the fact that Cuban doctors are trained free of charge by the Cuban government, unlike their counterparts in countries like the UK, who often graduate with significant student debt. The consequences of expelling Cuban doctors are severe. Millions could lose basic healthcare, with Indigenous communities particularly exposed. The region's healthcare systems, already fragile, are being strained, and the poorest will pay the price in untreated illnesses, unattended births, and undiagnosed cancers. Cuba has built a global medical network of more than 50,000 professionals working across dozens of countries, generating billions in foreign revenue and sustaining its economy under embargo. However, US pressure is disrupting this model, and Cuban medical personnel are being withdrawn, cutting off one of the island's few reliable sources of income. The Caribbean and Latin America are complicit in this economic warfare against Cuba. Sanctions restrict trade, finance, fuel, and medicine, shrinking economies, deepening poverty, and punishing citizens rather than governments. In Cuba, the effects are stark: blackouts, shortages, and collapsing productivity. A notable exception is Barbados, whose Prime Minister Mia Mottley has defended Cuba's medical missions and rejected the insinuation of "trafficking." She has made it clear that Barbados will stand by what is right, even at the cost of US punishments, highlighting that sovereignty is not merely constitutional but also moral.

Afika Bambaataa, the Bronx‑born architect of modern hip‑hop, passed away at age 67 in Philadelphia early Thursday morning, with officials citing complications from cancer as the cause of death. The Hip‑Hop Alliance, chaired by veteran rapper Kurtis Blow, released a statement honoring Bambaataa’s role as a founding figure of the culture. The group praised his creation of the Universal Zulu Nation, which promoted the movement’s core values of peace, unity, love and fun, while also acknowledging the complexity of his legacy in light of recent abuse allegations. During the 1980s, Bambaataa helped define the sound of hip‑hop, most notably with the 1982 electro‑funk anthem “Planet Rock”. The track, which sampled German pioneers Kraftwerk, positioned him at the forefront of a new musical frontier and led to collaborations with artists such as John Lydon, George Clinton and James Brown. Born Lance Taylor, he launched the Universal Zulu Nation in the late 1970s, drawing inspiration from DJ Kool Herc and the solidarity of South Africa’s Zulu people. This collective became a cultural hub that spread hip‑hop’s ethos worldwide. In the early 1980s Bambaataa also performed with the electronic group Ebn Ozn, further cementing his reputation as a bridge between American street culture and European synth‑pop. His work helped crystallize the electro‑funk genre that dominated clubs across the globe. His activist side emerged in 1985 when he joined Artists United Against Apartheid to produce the landmark protest single “Sun City.” The project featured a roster of high‑profile musicians—including Bob Dylan, Bono, Bruce Springsteen and Run‑DMC—united against South Africa’s apartheid regime. Throughout the 1990s and early 2000s Bambaataa continued to record, culminating in his final album, “Dark Matter Moving at the Speed of Light” (2004). While his musical output waned, his influence on subsequent generations of artists remained unmistakable. However, Bambaataa’s later years were marred by serious accusations. In 2016, several Bronx men alleged sexual misconduct, which he publicly dismissed as “baseless and cowardly.” A former bodyguard later claimed to have witnessed inappropriate behavior involving teenage boys. The allegations resurfaced in May 2025 when an anonymous plaintiff filed a civil suit alleging four years of abuse beginning in 1992. Bambaataa failed to appear in court, resulting in a default judgment against him. As the hip‑hop community mourns a foundational artist, it also confronts the enduring debate over how to reconcile his cultural contributions with the serious allegations that have come to define the final chapter of his public life.